JP2003501379A - ガン治療のための薬剤を充填したナノパーティクルの使用 - Google Patents

ガン治療のための薬剤を充填したナノパーティクルの使用

Info

Publication number: JP2003501379A
Authority: JP; Japan
Prior art keywords: nanoparticles; mammal; treatment; cancer; polysorbate
Prior art date: 1999-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2001501195A

Other languages

English (en)

Japanese (ja)

Inventor

ザーベル、ベルンハルト、アー．

クロイター、ヨルク

ゲルペリナ、スヴェトラナ

シュレーダー、ウルリケ

Original Assignee

ナノファーマアーゲー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-02

Filing date

1999-06-02

Publication date

2003-01-14

1999-06-02 Application filed by ナノファーマアーゲー filed Critical ナノファーマアーゲー

2003-01-14 Publication of JP2003501379A publication Critical patent/JP2003501379A/ja

Status Pending legal-status Critical Current

Links

239000002105 nanoparticle Substances 0.000 title claims abstract description 86
238000011282 treatment Methods 0.000 title claims abstract description 40
206010028980 Neoplasm Diseases 0.000 title claims abstract description 38
201000011510 cancer Diseases 0.000 title claims abstract description 32
239000000126 substance Substances 0.000 claims abstract description 48
208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 19
239000003814 drug Substances 0.000 claims abstract description 15
238000000034 method Methods 0.000 claims abstract description 9
230000008569 process Effects 0.000 claims abstract description 7
241000124008 Mammalia Species 0.000 claims description 37
239000003381 stabilizer Substances 0.000 claims description 26
239000004094 surface-active agent Substances 0.000 claims description 25
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 22
239000000463 material Substances 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 15
239000002246 antineoplastic agent Substances 0.000 claims description 12
229920000136 polysorbate Polymers 0.000 claims description 12
238000000576 coating method Methods 0.000 claims description 11
229960004679 doxorubicin Drugs 0.000 claims description 11
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 11
229920000053 polysorbate 80 Polymers 0.000 claims description 11
229920002307 Dextran Polymers 0.000 claims description 10
239000002184 metal Substances 0.000 claims description 10
229910052751 metal Inorganic materials 0.000 claims description 10
230000001766 physiological effect Effects 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
239000011248 coating agent Substances 0.000 claims description 9
-1 sulphate alcohols Chemical class 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 8
210000001218 blood-brain barrier Anatomy 0.000 claims description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
230000008499 blood brain barrier function Effects 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
229950008882 polysorbate Drugs 0.000 claims description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
229920002651 Polysorbate 85 Polymers 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
150000002989 phenols Chemical class 0.000 claims description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
229940068968 polysorbate 80 Drugs 0.000 claims description 4
229940113171 polysorbate 85 Drugs 0.000 claims description 4
229920002004 Pluronic® R Polymers 0.000 claims description 3
230000001093 anti-cancer Effects 0.000 claims description 3
150000002170 ethers Chemical class 0.000 claims description 3
150000004665 fatty acids Chemical class 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000002861 polymer material Substances 0.000 claims description 3
150000003626 triacylglycerols Chemical class 0.000 claims description 3
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 claims description 2
102000009027 Albumins Human genes 0.000 claims description 2
108010088751 Albumins Proteins 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
108010010803 Gelatin Proteins 0.000 claims description 2
241001465754 Metazoa Species 0.000 claims description 2
229920001710 Polyorthoester Polymers 0.000 claims description 2
229920001213 Polysorbate 20 Polymers 0.000 claims description 2
229920001219 Polysorbate 40 Polymers 0.000 claims description 2
229920001214 Polysorbate 60 Polymers 0.000 claims description 2
239000004793 Polystyrene Substances 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 2
229930013930 alkaloid Natural products 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
229940100198 alkylating agent Drugs 0.000 claims description 2
239000002168 alkylating agent Substances 0.000 claims description 2
239000003098 androgen Substances 0.000 claims description 2
229940030486 androgens Drugs 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
229940046836 anti-estrogen Drugs 0.000 claims description 2
230000000340 anti-metabolite Effects 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
229940100197 antimetabolite Drugs 0.000 claims description 2
239000002256 antimetabolite Substances 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
239000000872 buffer Substances 0.000 claims description 2
150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
150000001735 carboxylic acids Chemical class 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
229940127089 cytotoxic agent Drugs 0.000 claims description 2
229960002086 dextran Drugs 0.000 claims description 2
229940011871 estrogen Drugs 0.000 claims description 2
239000000262 estrogen Substances 0.000 claims description 2
239000000328 estrogen antagonist Substances 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229960001156 mitoxantrone Drugs 0.000 claims description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
229920002401 polyacrylamide Polymers 0.000 claims description 2
229920000058 polyacrylate Polymers 0.000 claims description 2
229920002721 polycyanoacrylate Polymers 0.000 claims description 2
229920000193 polymethacrylate Polymers 0.000 claims description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
229940068977 polysorbate 20 Drugs 0.000 claims description 2
229940101027 polysorbate 40 Drugs 0.000 claims description 2
229940113124 polysorbate 60 Drugs 0.000 claims description 2
229920002223 polystyrene Polymers 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
239000000243 solution Substances 0.000 claims description 2
239000001593 sorbitan monooleate Substances 0.000 claims description 2
235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
229940035049 sorbitan monooleate Drugs 0.000 claims description 2
239000001587 sorbitan monostearate Substances 0.000 claims description 2
235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
229940035048 sorbitan monostearate Drugs 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
229910021653 sulphate ion Inorganic materials 0.000 claims description 2
229920002554 vinyl polymer Polymers 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 1
150000001298 alcohols Chemical class 0.000 claims 1
230000001833 anti-estrogenic effect Effects 0.000 claims 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 claims 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
229940046085 endocrine therapy drug gonadotropin releasing hormone analogues Drugs 0.000 claims 1
150000002224 folic acids Chemical class 0.000 claims 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
238000007912 intraperitoneal administration Methods 0.000 claims 1
229960004961 mechlorethamine Drugs 0.000 claims 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
150000003057 platinum Chemical class 0.000 claims 1
229940068965 polysorbates Drugs 0.000 claims 1
125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
150000003230 pyrimidines Chemical class 0.000 claims 1
159000000000 sodium salts Chemical class 0.000 claims 1
229940079593 drug Drugs 0.000 abstract description 12
210000004556 brain Anatomy 0.000 abstract description 10
230000001506 immunosuppresive effect Effects 0.000 abstract description 4
230000000694 effects Effects 0.000 abstract description 3
238000002360 preparation method Methods 0.000 abstract description 3
230000004083 survival effect Effects 0.000 description 7
241000282412 Homo Species 0.000 description 6
241000700159 Rattus Species 0.000 description 5
229940041181 antineoplastic drug Drugs 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
241000699670 Mus sp. Species 0.000 description 3
238000011394 anticancer treatment Methods 0.000 description 3
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
229960004630 chlorambucil Drugs 0.000 description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
238000002513 implantation Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
230000000947 anti-immunosuppressive effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000004378 blood-retinal barrier Effects 0.000 description 1
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
229960002719 buserelin Drugs 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960001420 nimustine Drugs 0.000 description 1
VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000002745 poly(ortho ester) Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000013875 sodium salts of fatty acid Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
229960005353 testolactone Drugs 0.000 description 1
BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
229960000875 trofosfamide Drugs 0.000 description 1
UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Nanotechnology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP2001501195A 1999-06-02 1999-06-02 ガン治療のための薬剤を充填したナノパーティクルの使用 Pending JP2003501379A (ja)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP1999/003838 WO2000074658A1 (fr)	1999-06-02	1999-06-02	Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux

Publications (1)

Publication Number	Publication Date
JP2003501379A true JP2003501379A (ja)	2003-01-14

Family

ID=8167319

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2001501195A Pending JP2003501379A (ja)	1999-06-02	1999-06-02	ガン治療のための薬剤を充填したナノパーティクルの使用

Country Status (4)

Country	Link
EP (1)	EP1100475A1 (fr)
JP (1)	JP2003501379A (fr)
AU (1)	AU4373499A (fr)
WO (1)	WO2000074658A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007037474A1 (fr)	2005-09-30	2007-04-05	Tti Ellebeau, Inc.	Structure d'electrode pour iontophorese utilisee pour administrer un medicament contenu dans une microparticule et dispositif d'iontophorese utilisant cette structure
WO2008044705A1 (fr)	2006-10-10	2008-04-17	Tti Ellebeau, Inc.	dispositif d'ionophorèse de type dent artificielLE
JP2008207137A (ja) *	2007-02-28	2008-09-11	Shoichi Shirotake	異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法
US7848801B2 (en)	2005-12-30	2010-12-07	Tti Ellebeau, Inc.	Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
CN103623424A (zh) *	2012-08-24	2014-03-12	复旦大学	一种基于聚甲基丙烯酸酯的脑靶向基因递释系统
JP2015521198A (ja) *	2012-05-29	2015-07-27	ザユニバーシティオブバーミンガム	付着したｄｎａ修復阻害剤及び核局在化シグナル要素を含むナノパーティクル

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2218685T3 (es)	1997-06-13	2004-11-16	Nanodel Technologies Gmbh	Sistema para direccion de farmaco, procedimiento para su preparacion y su utilizacion.
US7153525B1 (en)	2000-03-22	2006-12-26	The University Of Kentucky Research Foundation	Microemulsions as precursors to solid nanoparticles
AUPR011700A0 (en)	2000-09-14	2000-10-05	Austin Research Institute, The	Composition comprising immunogenic virus sized particles (VSP)
DE10121982B4 (de) *	2001-05-05	2008-01-24	Lts Lohmann Therapie-Systeme Ag	Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003028700A2 (fr) *	2001-09-28	2003-04-10	Solubest Ltd.	Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes et dispositif et procede de fabrication de celles-ci
US6878693B2 (en)	2001-09-28	2005-04-12	Solubest Ltd.	Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7763663B2 (en)	2001-12-19	2010-07-27	University Of Massachusetts	Polysaccharide-containing block copolymer particles and uses thereof
AU2002331356A1 (en) *	2002-07-29	2004-03-11	Nanodel Technologies Gmbh	Nanoparticles for dna administration to a target organ
US20060228420A1 (en) *	2005-03-15	2006-10-12	Queen Mary & Westfield College	Pharmaceutical compositions comprising microparticles for delivery into neurons
US9486408B2 (en)	2005-12-01	2016-11-08	University Of Massachusetts Lowell	Botulinum nanoemulsions
DE102005062440B4 (de) *	2005-12-27	2011-02-24	Lts Lohmann Therapie-Systeme Ag	Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
EP1985286A1 (fr) *	2007-04-24	2008-10-29	Biocompatibles UK Limited	Microsphères pour le traitement de tumeurs cérébrales
WO2010040173A1 (fr) *	2008-10-08	2010-04-15	Commonwealth Scientific And Industrial Research Organisation	Procédé d'administration d'agents fonctionnels à travers la barrière hémato-encéphalique
AU2017360346B2 (en)	2016-11-21	2023-11-23	Eirion Therapeutics, Inc.	Transdermal delivery of large agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2634397B2 (fr) *	1986-12-31	1991-04-19	Centre Nat Rech Scient	Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
WO1995022963A1 (fr) *	1994-02-28	1995-08-31	Medinova Medical Consulting Gmbh	Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
ES2218685T3 (es) *	1997-06-13	2004-11-16	Nanodel Technologies Gmbh	Sistema para direccion de farmaco, procedimiento para su preparacion y su utilizacion.
DE19745950A1 (de) *	1997-10-17	1999-04-22	Dds Drug Delivery Service Ges	Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

1999
- 1999-06-02 EP EP99926509A patent/EP1100475A1/fr not_active Ceased
- 1999-06-02 JP JP2001501195A patent/JP2003501379A/ja active Pending
- 1999-06-02 WO PCT/EP1999/003838 patent/WO2000074658A1/fr not_active Ceased
- 1999-06-02 AU AU43734/99A patent/AU4373499A/en not_active Abandoned

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007037474A1 (fr)	2005-09-30	2007-04-05	Tti Ellebeau, Inc.	Structure d'electrode pour iontophorese utilisee pour administrer un medicament contenu dans une microparticule et dispositif d'iontophorese utilisant cette structure
US7848801B2 (en)	2005-12-30	2010-12-07	Tti Ellebeau, Inc.	Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
WO2008044705A1 (fr)	2006-10-10	2008-04-17	Tti Ellebeau, Inc.	dispositif d'ionophorèse de type dent artificielLE
JP2008207137A (ja) *	2007-02-28	2008-09-11	Shoichi Shirotake	異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法
JP2015521198A (ja) *	2012-05-29	2015-07-27	ザユニバーシティオブバーミンガム	付着したｄｎａ修復阻害剤及び核局在化シグナル要素を含むナノパーティクル
CN103623424A (zh) *	2012-08-24	2014-03-12	复旦大学	一种基于聚甲基丙烯酸酯的脑靶向基因递释系统
CN103623424B (zh) *	2012-08-24	2016-08-03	复旦大学	一种基于聚甲基丙烯酸酯的脑靶向基因递释系统

Also Published As

Publication number	Publication date
AU4373499A (en)	2000-12-28
EP1100475A1 (fr)	2001-05-23
WO2000074658A1 (fr)	2000-12-14

Publication	Publication Date	Title
JP2003501379A (ja)	2003-01-14	ガン治療のための薬剤を充填したナノパーティクルの使用
JP2930421B2 (ja)	1999-08-03	薬剤組成物、その製造方法及びその使用方法
EP2262478B1 (fr)	2014-11-05	Donneurs d' oxyde nitrique activés et méthodes de fabrication et d' utilisation associées
US20020119916A1 (en)	2002-08-29	Elemental nanoparticles of substantially water insoluble materials
CA2371912A1 (fr)	2000-11-30	Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
TW200817047A (en)	2008-04-16	Drug microparticles
CA2539542A1 (fr)	2005-04-07	Transport de composes therapeutiques par le biais de microparticules ou de microbulles
WO2007028341A1 (fr)	2007-03-15	Nanomicelles servant de medicaments anticancereux a polyethylene phospholipides glycolyles contenant des vinca alcaloides
KR20110056042A (ko)	2011-05-26	종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
SK288246B6 (sk)	2015-03-03	Použitie esterov L-karnitínu alebo alkanoyl-L-karnitínov ako katiónových lipidov na vnútrobunkové dodávanie farmakologicky účinných zlúčenín
KR20160142283A (ko)	2016-12-12	아연 프로토포르피린의 마이크로입자 전달용 제형물
US20070042046A1 (en)	2007-02-22	Methods for the treatment of cancer
CN106913882A (zh)	2017-07-04	一种聚乙二醇‑藤黄酸脂质体和制备方法及其在治疗恶性肿瘤中的应用
AU2005284909A1 (en)	2006-03-23	Delivering iron to an animal
WO2006069344A2 (fr)	2006-06-29	Hydrogels a liberation regulee
US20230074885A1 (en)	2023-03-09	Bortezomib-loaded nanoparticles
US11246836B2 (en)	2022-02-15	Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof
CN112741828B (zh)	2022-04-26	药物联用物及其制备方法和用途
EP1872798B1 (fr)	2013-06-05	Agent anti-tumeur absorbable par l intestin
RU2670091C1 (ru)	2018-10-18	Способ доставки наночастиц, предназначенных для транспортировки лекарственных веществ, в головной мозг млекопитающих через гематоэнцефалический барьер
CN111840547B (zh)	2023-04-28	注射用培美曲塞磁性自组装纳米复合颗粒制备方法
KR20250156611A (ko)	2025-11-03	폐동맥 고혈압 표적 치료용 세포막 유래 산화질소 나노 전달체 및 이의 제조방법
Surendran et al.	2024	THERAPEUTIC ACTIVITIES OF CINNAMIC ACID AND ITS VARIOUS DRUG DELIVERY STRATEGIES: AN INSIGHT
WO2007014150A2 (fr)	2007-02-01	Procede d'administration de liposomes contenant des oligonucleotides
CN113045464A (zh)	2021-06-29	制剂、纳米药物、纳米颗粒及其制备方法、应用

Legal Events

Date	Code	Title	Description
2006-05-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060515
2006-10-13	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061012

Date

Code

Title

Description

2006-05-16

A131

Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060515

2006-10-13

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061012